Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

375 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).
Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, Crowley J, Hu C, Stevens RM, Shah K, Day RM, Girolomoni G, Gottlieb AB. Paul C, et al. Among authors: ferrandiz c. Br J Dermatol. 2015 Dec;173(6):1387-99. doi: 10.1111/bjd.14164. Epub 2015 Nov 7. Br J Dermatol. 2015. PMID: 26357944 Clinical Trial.
Patient-relevant needs and treatment goals in nail psoriasis.
Blome C, Costanzo A, Dauden E, Ferrandiz C, Girolomoni G, Gniadecki R, Iversen L, Menter A, Michaelis-Wittern K, Morita A, Nakagawa H, Reich K, Augustin M. Blome C, et al. Among authors: ferrandiz c. Qual Life Res. 2016 May;25(5):1179-88. doi: 10.1007/s11136-015-1136-y. Epub 2015 Oct 3. Qual Life Res. 2016. PMID: 26433952
Paradoxical eczematous reaction to ixekizumab.
Munera-Campos M, Ballesca F, Richarz N, Ferrandiz C, Carrascosa JM. Munera-Campos M, et al. Among authors: ferrandiz c. J Eur Acad Dermatol Venereol. 2019 Jan;33(1):e40-e42. doi: 10.1111/jdv.15156. Epub 2018 Aug 13. J Eur Acad Dermatol Venereol. 2019. PMID: 29953678 No abstract available.
Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry.
Carrascosa JM, Vilavella M, Garcia-Doval I, Carretero G, Vanaclocha F, Daudén E, Gómez-García FJ, Herrera-Ceballos E, De la Cueva Dobao P, Belinchón I, Sánchez-Carazo JL, Alsina M, López-Estebaranz JL, Ferrán M, Peral F, Torrado R, Rivera R, Jiménez-Puya R, Mendiola MV, Ferrándiz C; BIOBADADERM Study Group. Carrascosa JM, et al. Among authors: ferrandiz c. J Eur Acad Dermatol Venereol. 2014 Jul;28(7):907-14. doi: 10.1111/jdv.12208. Epub 2013 Jul 15. J Eur Acad Dermatol Venereol. 2014. PMID: 23848131
375 results